Clinical Trials Logo

Advanced Renal Cell Carcinoma clinical trials

View clinical trials related to Advanced Renal Cell Carcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04203901 Terminated - Clinical trials for Advanced Renal Cell Carcinoma

Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Start date: July 22, 2020
Phase: Phase 2
Study type: Interventional

CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active components of CMN-001 are autologous, matured dendritic cells, which have been co-electroporated with both in vitro transcribed (IVT) RNA from an autologous tumor specimen and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st line failure.

NCT ID: NCT01727336 Terminated - Clinical trials for Advanced Renal Cell Carcinoma

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

Start date: December 2012
Phase: Phase 2
Study type: Interventional

The purpose of Part 1 of this study is to evaluate the safety and tolerability of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (RCC) to determine the recommended dose level of dalantercept in combination with axitinib for Part 2. The purpose of Part 2 of this study is to determine whether treatment with dalantercept in combination with axitinib prolongs progression free survival (PFS) compared to axitinib alone in patients with advanced renal cell carcinoma (RCC).

NCT ID: NCT01582672 Terminated - Clinical trials for Renal Cell Carcinoma

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

ADAPT
Start date: November 2012
Phase: Phase 3
Study type: Interventional

This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone.